



# Health Technology Assessment (HTA) Consumer Consultative Committee (CCC)

## HTA CCC Communique – 19 February 2025 28th Meeting of the HTA CCC

### Attendees

Consumer representatives from the Pharmaceutical Benefits Advisory Committee (PBAC) and its subcommittees, the Medical Services Advisory Committee (MSAC) and its subcommittees, the Life Saving Drugs Program (LSDP) Expert Panel, the Medicare Benefits Schedule Review Advisory Committee (MRAC) and the Medical Devices and Human Tissue Advisory Committee (MDHTAC).

Representatives from the National Aboriginal Community Controlled Health Organisation (NACCHO) as guest speakers for a workshop presentation.

Departmental representatives from the Consumer Evidence and Engagement Unit (CEEU).

### Outcomes

The HTA Consumer Consultative Committee (HTA CCC) reflected on the current processes used for consumer organisations and individuals' inputs, provided to inform HTA committees' deliberations and bring context to the evidence included in HTA submissions/applications. The consumer member role is to ensure HTA committees and subcommittees are aware of the perspectives, needs and impacts that a health technology item may have on consumers. The HTA CCC considered aspects such as health literacy, variability in consumer organisations' capacity to provide input and the need to provide feedback on consumer input.

The Chair welcomed representatives from the National Aboriginal Community Controlled Health Organisation (NACCHO) to conduct a workshop: 'Aboriginal and Torres Strait Islander perspectives in HTA'.

NACCHO provided the HTA CCC with an overview of the organisation's history, its Aboriginal Community Controlled Health Organisations (ACCHO) structure and its broad scope of work. Insights into the NACCHO approach to the health technology life cycle were discussed. Its goal is to achieve Aboriginal and Torres Strait Islander oversight and representation throughout the life cycle, from clinical research and continuing beyond health technology assessment into post-market considerations such as medicines repurposing.

Specific to the HTA context, NACCHO discussed its methods for identifying items on HTA committee agendas that are priorities for Aboriginal and Torres Strait Islander communities. ACCHOs are consulted to create a collective NACCHO input on these items, for HTA committee considerations.

On behalf of the HTA CCC, the Chair thanked NACCHO for its time in speaking with the committee, noting the value of the information and discussion during the workshop for the consumer representatives on HTA committees and subcommittees.

Following the workshop, the HTA CCC reflected on the valuable insights gained from the session. Consideration was given to how consumer representatives on HTA committees and

subcommittees may share the key learnings from the workshop with their respective HTA committees. Suggestions were proposed on potential ways that Aboriginal and Torres Strait Islander needs, perspectives and challenges in their health care may be better identified and communicated within HTA committee deliberations.

Updates on activities and items of note were provided by the Chair, consumer representatives and the Consumer Evidence and Engagement Unit (CEEU). A proposed 2025 communication strategy was presented by the CEEU, outlining key objectives for planned e-newsletters and webinars during the year ahead. The HTA CCC discussed and agreed to topics for further exploration at future meetings.

The next HTA CCC meeting is scheduled to be held in May 2025.